Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Danaher, DHR
Summary: Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally.
- Last Price: $242.33
- Price Change: -$3.24, -1.32%
- Yearly Gain: -3.12%
- Market Cap: $181.21B
- P/E Ratio: 26.11
Here are 3rd party ratings for DHR:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 39% (98 out of 249)
What is the sentiment on the street regarding Danaher ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in DHR or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on DHR before you decide to make any investment.
Click here for chart >>
Catalyst Pharma, CPRX
Summary: Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.'The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.'Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
- Last Price: $16.66
- Price Change: $0.06, 0.36%
- Yearly Gain: 116.90%
- Market Cap: $1.76B
- P/E Ratio: 22.683
Here are 3rd party ratings for CPRX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 46% (114 out of 249)
What is the sentiment on the street regarding Catalyst Pharma ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Neutral
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in CPRX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CPRX before you decide to make any investment.
Click here for chart >>
BioCryst, BCRX
Summary: BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
- Last Price: $8.47
- Price Change: $0.18, 2.17%
- Yearly Gain: -18.57%
- Market Cap: $1.56B
- P/E Ratio: -6.844
Here are 3rd party ratings for BCRX:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 46% (114 out of 249)
What is the sentiment on the street regarding BioCryst ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Low
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in BCRX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on BCRX before you decide to make any investment.
Click here for chart >>
Thanks for reading!